BioLargo’s upgraded Aqueous Electrostatic Concentrator (AEC) now cuts energy consumption by more than 90% for large‑scale PFAS treatment in drinking water, while maintaining the same 99% removal efficiency as earlier generations.
The new design delivers up to 80% total life‑cycle cost savings versus conventional granular activated carbon and ion‑exchange systems, and concentrates PFAS into a waste stream that is 1/40,000 the volume of GAC‑based waste, reducing hazardous by‑product handling and operating expenses.
In Q2 2025, BioLargo reported revenues of $2.777 million, a decline from the prior year largely due to lower sales of its Pooph pet‑odor product. The company continues to record losses and negative cash flow, raising doubts about its ability to continue as a going concern.
The AEC upgrade is part of BioLargo’s ONM Environmental segment, which also includes other water‑treatment technologies. The company’s other business lines—Clyra Medical and battery technology—have not yet reached commercial scale and contribute modestly to overall revenue.
Management highlighted that the energy‑efficiency breakthrough is a key lever to improve margins and competitiveness in the growing PFAS remediation market, and that the lower operating costs will make the AEC more attractive to municipalities and industrial customers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.